Atara Biotherapeutics Inc (NASDAQ:ATRA) – Equities research analysts at William Blair issued their FY2022 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Tuesday. William Blair analyst M. Phipps anticipates that the biotechnology company will post earnings per share of ($1.74) for the year.
A number of other research analysts have also issued reports on ATRA. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, November 9th. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target on the stock in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Cowen started coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $30.60.
Several hedge funds have recently added to or reduced their stakes in the company. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Atara Biotherapeutics by 13.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 3,146,820 shares of the biotechnology company’s stock valued at $56,957,000 after acquiring an additional 371,099 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new stake in Atara Biotherapeutics during the fourth quarter worth $23,284,000. Neuberger Berman Group LLC boosted its holdings in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after buying an additional 147,061 shares in the last quarter. Artal Group S.A. boosted its holdings in Atara Biotherapeutics by 66.7% during the fourth quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $18,100,000 after buying an additional 400,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Atara Biotherapeutics by 1.7% during the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after buying an additional 13,952 shares in the last quarter. 69.58% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Isaac E. Ciechanover sold 48,500 shares of the company’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $34.58, for a total value of $1,677,130.00. Following the sale, the chief executive officer now directly owns 348,978 shares of the company’s stock, valued at approximately $12,067,659.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gad Soffer sold 7,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $15.00, for a total transaction of $105,000.00. Following the completion of the sale, the executive vice president now directly owns 166,342 shares in the company, valued at $2,495,130. The disclosure for this sale can be found here. Insiders sold a total of 279,098 shares of company stock worth $7,155,400 over the last ninety days. Insiders own 16.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/atara-biotherapeutics-inc-atra-forecasted-to-post-fy2022-earnings-of-1-74-per-share.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.